March 19, 2004 — The Genome Institute of Singapore has adopted systems developed by Salt Lake City-based BioMicro Systems Inc. for microarray experiments, according to a news release.
The national institute bought seven of BioMicro’s MAUI, or Microarray User Interface systems for SARS and cancer studies. An institute leader said in the release that the systems provide ease of use, small volumes as well as high uniformity and sensitivity.
The MAUI system is designed to simultaneously process up to four microarray slides, using what BioMicro calls the industry’s smallest microarray hybridization chamber with integrated mixing.